Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorWashington University School of Medicine

About this trial

Despite strong evidence that tight control of blood sugar reduces the risk of diabetes complications, most people with type 1 diabetes do not achieve recommended blood sugar targets. This randomized controlled trial will test whether a very-low- carbohydrate ketogenic diet can effectively and safely improve blood sugar control in adults with type 1 diabetes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 and ≤65 years

T1D diagnosed >1 year prior to screening

HbA1c 7.0%-9.0%

Stable insulin delivery method for the past 30 days

Disqualifiers

Body mass index <20.0 or >34.9 kg/m2

Severe gastroparesis or history of bariatric surgery

Diabetes-related hospitalization (including for diabetic ketoacidosis or severe hypoglycemia) within 12 months of screening

Poorly controlled hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ketogenic Diet

    Behavioral

    Participants will consume a very-low-carbohydrate ketogenic diet for 12 weeks.

  • Standard Diet

    Behavioral

    Participants will consume an American Diabetes Association-recommended standard diet for 12 weeks.

Treatment groups

58 Participants
are divided into 2 treatment groups
Group A: Ketogenic DietExperimental treatment 1 intervention
Group B: Standard CareActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in continuous glucose monitor (CGM) time-in-range

Interstitial glucose percent time in range assessed by using a continuous glucose monitor

Time frame
Before and immediately after the dietary intervention
2

Change in skeletal muscle insulin sensitivity

Insulin sensitivity will be determined by the hyperinsulinemic-euglycemic clamp procedure

Time frame
Before and immediately after the dietary intervention

Secondary outcomes

1

Change in daily insulin requirements

The daily total dose of insulin used will be assessed

Time frame
Assessed before, during, and immediately after the dietary intervention
2

Change in 24-hour glucose concentrations

Plasma glucose concentrations will be evaluated from frequent blood samples over a 24 hour period

Time frame
Before and immediately after the dietary intervention
3

Change in 24-hour glucagon concentrations

Plasma glucagon concentrations will be evaluated from frequent blood samples over a 24 hour period

Time frame
Before and immediately after the dietary intervention
4

Change in whole-body palmitate turnover

Palmitate turnover will be measured by isotope dilution

Time frame
Before and immediately after the dietary intervention

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.